1-9 of 9
drug level below therapeutic
Close
Sort by
Journal Articles

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

Cassie Chou, MD PhD, Simon Fraessle, Rachel Steinmetz, BSc, Reed M. Hawkins, BS, Tinh-Doan Phi, BS, Dirk Busch, Takahiro Miyazaki, Mario Q. Marcondes, MD PhD, Stanley R. Riddell, MD, Cameron J. Turtle, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2866.
https://doi.org/10.1182/blood-2019-125960
Published: 2019
Journal Articles

iNKT Cell Stimulation with Liposomal Alpha/Gal/Cer Amplifies Proliferation of Adoptively Transferred Regulatory T Cells In Vivo and Reduces GvHD

Toshihito Hirai, MD PhD, Federico Simonetta, MD PhD, Kristina Maas-Bauer, MD, Melissa Mavers, MD PhD, Jeanette Baker, Robert S. Negrin, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4519.
https://doi.org/10.1182/blood-2018-99-109836
Published: 2018
Journal Articles

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

Pritesh Patel, MD, Vitalyi Senyuk, PhD, Natalie S. Rodriguez, MS, Dolores Mahmud, PhD, Annie Lee Oh, MD, Nadim Mahmud, MBBS, PhD, Giovanni Barosi, MD, Damiano Rondelli, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3319.
https://doi.org/10.1182/blood-2018-99-119497
Published: 2018
Journal Articles

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Christine O'Day, PhD, Steve Alley, PhD, Martha Anderson, Kim Emmerton, Weipeng Zeng, Megan M. O'Meara, MD, Eric J. Feldman, MD, Dana A. Kennedy, Maureen C. Ryan, PhD, Dennis Benjamin, PhD
Journal: Blood
Blood (2015) 126 (23): 3785.
https://doi.org/10.1182/blood.V126.23.3785.3785
Published: 2015
Journal Articles

Strategies to Prevent or Reverse Immune Responses Against Factor In Gene Replacement for Hemophilia B.

Sushrusha Nayak, PhD, Babak Moghimi, MD, Roland W Herzog, PhD
Journal: Blood
Blood (2010) 116 (21): 3761.
https://doi.org/10.1182/blood.V116.21.3761.3761
Published: 2010
Journal Articles

The mTOR Inhibitor RAD001 (Everolimus) Improves Survival in Preclinical Models of Primary Human ALL.

Roman Crazzolara, MD, Adam Cisterne, BSc, Marilyn Thien, Bsc, PhD, John Hewson, MD, Kenneth Francis Bradstock, MD, PhD, Linda J. Bendall, BSc, PhD
Journal: Blood
Blood (2007) 110 (11): 856.
https://doi.org/10.1182/blood.V110.11.856.856
Published: 2007
Journal Articles

Combination of Akt/PKB Inhibition (Perifosine) and Farnesyl Transferase Inhibition (Tipifarnib) Results in Increased Cell Death in Myeloma Cells Lines.

Rajni Sinha, MD, Ebenezer David, PhD, Emily Zeilter, Claire Torre, Jonathan L. Kaufman, MD, Sagar Lonial, MD
Journal: Blood
Blood (2005) 106 (11): 1568.
https://doi.org/10.1182/blood.V106.11.1568.1568
Published: 2005
Journal Articles

Enhanced Levels of Apoptosis by Combination of Farnesyl Transferase Inhibition (Tipifarnib) and Proteasome Inhibition (Bortezomib) in Myeloma Cell Lines and Primary Myeloma Cells and Its Mechanistic Effects on Akt and Caspase Pathways.

Jonathan L. Kaufman, MD, Ebenezer David2, PhD, Claire Torre3, Rajni Sinha4, MD, Sagar Lonial5, MD
Journal: Blood
Blood (2005) 106 (11): 1573.
https://doi.org/10.1182/blood.V106.11.1573.1573
Published: 2005
Journal Articles

Dose Response of Deferoxamine, Deferiprone, and ICL670 Chelation Therapy in a Gerbil Model of Iron Overload.

John C. Wood, MD, PhD, Maya Otto-Duessel, MS, Michelle Aguilar, BS, Hanspeter Nick, PhD, Thomas D. Coates, MD, Moats Rex, PhD
Journal: Blood
Blood (2004) 104 (11): 3621.
https://doi.org/10.1182/blood.V104.11.3621.3621
Published: 2004